The Cooper Companies Inc COO

Morningstar Rating
$109.75 +0.01 (< 0.01%)
View Full Chart

Company Report

CooperCompanies Earnings: Solid Result From Wins Across Portfolio and Margin Expansion

Narrow-moat CooperCompanies reported solid third-quarter results that came in slightly ahead of our expectations. Total sales of $1.0 billion were up 7.9% year over year thanks to a broad-based growth across the firm. CooperVision was up 7.3% despite lapping last year’s double-digit growth, and we attribute this to growing demand and solid execution. Capacity constraints continue to ease but demand still looks to be outpacing supply, especially within the MyDay portfolio, and we think resolving this will be a multiquarter workout. CooperSurgical, up 9.1%, continues to impress us with its ability to consistently deliver solid numbers. Against the backdrop of strong performance, Cooper raised its sales guidance about 2% at midpoint driven by an improved outlook in both business units. After updating our model and accounting for time value of money, we raise our fair value estimate to $90 per share from $88.

Price vs Fair Value

COO is trading at a 469% premium.
Price
$109.78
Fair Value
$97.00
Uncertainty
Medium
1-Star Price
$944.60
5-Star Price
$15.00
Economic Moat
Jcfqf
Capital Allocation
Xdjgxhqh

Bulls Say, Bears Say

Bulls

Cooper is one of the leading visioncare companies in the world with a proven record of successful product development. It will continue to launch technically superior products over the long term.

Bears

While the contact lens market share has been stable, lagging research and innovation could start to chip away at Cooper's presence in the space.

News

Trading Information

Previous Close Price
$109.74
Day Range
$109.63110.71
52-Week Range
$76.02112.27
Bid/Ask
$109.58 / $109.77
Market Cap
$21.85 Bil
Volume/Avg
184,590 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
31.12
Price/Sales
5.77
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Core
Total Number of Employees
15,000

Competitors

Valuation

Metric
COO
JNJ
Price/Earnings (Normalized)
31.1215.40
Price/Book Value
2.765.43
Price/Sales
5.774.58
Price/Cash Flow
23.1717.42
Price/Earnings
COO
JNJ

Financial Strength

Metric
COO
JNJ
Quick Ratio
0.880.77
Current Ratio
1.991.07
Interest Coverage
5.5824.45
Quick Ratio
COO
JNJ

Profitability

Metric
COO
JNJ
Return on Assets (Normalized)
3.02%13.17%
Return on Equity (Normalized)
4.67%32.42%
Return on Invested Capital (Normalized)
4.23%20.93%
Return on Assets
COO
JNJ

Medical Instruments & Supplies Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
NkzqxdvkdLqdl$170.3 Bil
Becton Dickinson & Co
BDX
KdlgbnqcBczqgx$69.8 Bil
Alcon Inc
ALC
GhhtnntlkQmkmhz$49.3 Bil
ResMed Inc
RMD
CwwvmtcqlqVtlzsm$35.1 Bil
Coloplast AS ADR
CLPBY
TspjsnjvMvs$29.7 Bil
West Pharmaceutical Services Inc
WST
FzppncgsKqd$22.6 Bil
Baxter International Inc
BAX
WrzncyhRftjhm$19.9 Bil
Align Technology Inc
ALGN
PqqjhkglsXnpcd$19.0 Bil
Hologic Inc
HOLX
MkglshfsFrwyln$18.8 Bil

Sponsor Center